This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Riva-Quetiapine 25 mg
- Starting date:
- May 17, 2013
- Posting date:
- June 4, 2013
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type I
- Source of recall:
- Health Canada
- Issue:
- Product Safety, Contamination
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-33885
Recalled products
- Riva-Quetiapine 25 mg
Reason
Potential cross-contamination of trace amounts of Clindamycin in Quetiapine Active Pharmaceutical Ingredient during the manufacturing process.
Depth of distribution
Wholesalers and pharmacies in Quebec, Ontario, and British-Columbia
Affected products
A. Riva-Quetiapine 25 mg
DIN, NPN, DIN-HIM
DIN 02316692
Dosage form
- Tablet
Strength
- 25 mg / tablet
Lot or serial number
Bottle size: 100 tabs
- P5135
- P5823
- C0444
- C0445
- C0446
Bottle size: 500 tabs
- P5136
- P5888
- C0447
- C0448
- C0449
Companies
- Recalling Firm
-
Laboratoire Riva Inc.
660 Industrial Blvd.
Blainville
J7C 3V4
Quebec
CANADA
- Marketing Authorization Holder
-
Laboratoire Riva Inc.
660 Industrial Blvd.
Blainville
J7C 3V4
Quebec
CANADA